



NDA 21964/S-018
NDA 208271/S-002

SUPPLEMENT APPROVAL

Salix Pharmaceuticals, Inc.
Attention: Mary Harrell
Director, Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, New Jersey 08807

Dear Ms. Harrell:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received June 23, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Relistor (methylnaltrexone bromide) subcutaneous injection, 20 mg/mL and 150 mg tablets.

These Prior Approval supplemental new drug applications provides the following changes as requested in our Prior Approval Supplement request letter dated May 23, 2017:

- clarification of the indications related to the treatment of opioid-induced constipation (OIC) in the Indications and Usage section of the Prescribing Information (PI) and Medication Guide
- revision of the administration instructions in the Dosage and Administration section of the PI

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Donna Griebel, M.D.
Director
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DONNA J GRIEBEL
08/01/2017